Organisation paid for research Program year 2025 Source: CMS Open Payments

Affiliated Dermatology

Neither a doctor nor a teaching hospital

Research payments

$398,644

416 payments

Through program year 2025, Affiliated Dermatology is reported as receiving $398,644 in research payments, across 416 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$207,903	233
2024	Research	$188,576	182
2023	Research	$2,165	1

Breakdown

Who paid Research payments · program years 2023–2025

Incyte Corporation $354,124 409 payments
Amgen Inc. $44,520 7 payments

Studies the money was for Research payments · program years 2023–2025

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. $177,363 121 payments
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $140,659 174 payments
ASCEND P3 AD Extension $30,886 2 payments
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa $11,388 13 payments
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream $10,102 3 payments
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $10,098 47 payments
VOYAGER P3 AD Vaccine Study $6,429 2 payments
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $4,540 1 payment
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $2,574 2 payments
P3 AD Vaccine Study $2,165 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.